MGMT and brain neoplasm: Pacritinib significantly reduced the vitality and sphere-forming capacity of brain tumor-initiating cells (BTICs) in vitro, according to Jensen et al. Pacritinib was also observed to boost temozolomide activity in BTIC cells with unmethylated MGMT (O-6-methylguanine-DNA methyltransferase) promoters.